Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 7/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 1/20 | 0.30 |
| ▸ | USP1 | O94782 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31397009 | 0.87 | TLR9 (0.35) | TLR9TLR7PRMT5GPR119GRM5 | |
| SCHEMBL23540926 | 0.86 | NAMPT (0.41) | PRMT5GPR119GRM5 | |
| SCHEMBL31397115 | 0.86 | GRM5 (0.33) | GRM5CDK9 | |
| SCHEMBL31397293 | 0.84 | GRM5 (0.32) | GRM5 | |
| SCHEMBL30273631 | 0.83 | TLR9 (0.36) | TLR9TLR7PRMT5GPR119GRM5 | |
| SCHEMBL31397182 | 0.83 | BRD4 (0.32) | GRM5 | |
| SCHEMBL31323560 | 0.82 | PRMT5 (0.37) | TLR9TLR7PRMT5GPR119TACR1 | |
| SCHEMBL30274078 | 0.81 | GPR119 (0.37) | TLR9TLR7PRMT5GPR119GRM5 | |
| SCHEMBL29197711 | 0.81 | PRMT5 (0.38) | TLR9TLR7PRMT5GPR119CCNT1 | |
| SCHEMBL30273826 | 0.81 | CYP11B2 (0.39) | TLR9TLR7PRMT5GPR119GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | CALICO LIFE SCIENCES LLC (US) | 2024-12-26 | — | — | US | disclosed |
| US-20240383886-A1 | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof | ABBVIE INC. | 2024-11-21 | — | — | US | disclosed |
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | C4 THERAPEUTICS, INC. | 2024-10-17 | — | — | US | disclosed |
| EP-4367113-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | Biogen MA Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-117940414-A | Compounds for targeting IRAK4 protein degradation | 渤健马萨诸塞州股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2023283610-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| EP-4077319-A1 | PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF | Calico Life Sciences LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021127586-A1 | PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127586-A1 | PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383886-A1 | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof | PTPN5, PTPN1, PTPN2 | TLR9 3540/4885TLR7 3575/4885PRMT5 303/4885 |
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | PTPN1, PTPN2, PTPN5 | TLR9 3300/4885TLR7 3400/4885PRMT5 2942/4885 |
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | IRAK4, IRAK2, IRAK1 | TLR9 224/4885TLR7 277/4885PRMT5 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.